Loading…
Continue Reading
Related articles from the knowledge base
TECHNOLOGY
Money is flowing into brain technology again. It is flowing unevenly, though, and not always toward the companies most people would name first.
Loading…
Continue Reading
Related articles from the knowledge base
FREQUENTLY ASKED
The most consistently active all-around backer is Khosla Ventures, while Dolby Family Ventures is the deepest dedicated specialist. Other documented names include Prime Movers Lab, ARCH Venture Partners, Lightspeed Venture Partners, Founders Fund, In-Q-Tel, and Lux Capital. There is no single objective ranking, because most investors appear in only one qualifying round per period.
Funding comes from four main groups: * Specialists: Dolby Family Ventures, Prime Movers Lab, Nexus NeuroTech Ventures * Active generalists: Khosla Ventures, Lightspeed, Founders Fund * Deep-tech, bio, and strategic capital: ARCH Venture Partners, In-Q-Tel, sovereign funds * Regional leaders: IDG Capital in China
Documented BCI backers include Khosla Ventures and ARCH Venture Partners (Synchron), Lightspeed and Khosla (Science Corporation), Founders Fund (Neuralink, Blackrock Neurotech), Prime Movers Lab and Dolby Family Ventures (Paradromics), and In-Q-Tel (Synchron, Science Corp.). In China, IDG Capital co-led BrainCo's 2026 round.
Neuromodulation covers stimulation-based treatment for depression, chronic pain, epilepsy, and movement disorders, and it draws both specialist and health-focused capital. Dolby Family Ventures has exposure through Cala Health and Magnus Medical, and the category attracted more total venture capital than any other neurotech segment in H1 2026.
Consumer neurotech tends to attract generalist and early-stage backers. Khosla Ventures funded the sleep-wearable company Somnee, IDG Capital backed BrainCo, and early-stage investors such as TurboStart and IdeaBaaz seeded smaller players like Sychedelic.
Look at the portfolio, not the brand. A genuine neurotech investor shows documented, repeated exposure across brain-tech companies, ideally with follow-on checks. A single stake in one famous BCI round is exposure, not evidence of a dedicated thesis.
Neurotech startups raised about $2.64 billion across 81 disclosed financing events in the first half of 2026, according to Neurofounders. The capital was highly concentrated: roughly 13 rounds of $50 million or more accounted for about three-quarters of the total, and only around 22% of mapped companies raised at all.
The largest single rounds in 2026 came from the brain-computer interface sector. Merge Labs raised a $252 million seed in January, Science Corporation raised $230 million in March, and in China, BrainCo raised about $288 million.
Khosla Ventures is the most active all-around neurotech investor in 2026. It backed three unrelated brain-tech companies in recent rounds: Synchron, Science Corporation, and the sleep-neurotech company Somnee.
Neurotech is drawing record venture interest, but the opportunity is uneven. Capital is concentrated in a small group of brain-computer interface and neuromodulation leaders, while most companies raise little or nothing. The field also carries long timelines and regulatory risk, so it suits investors comfortable with deep-tech and clinical-stage uncertainty. This is market context, not investment advice.
Consumer neurotech wearables are typically funded by generalist and early-stage investors rather than clinical-device specialists. Examples include Khosla Ventures (the sleep headband Somnee), IDG Capital (BrainCo), and seed investors such as TurboStart and IdeaBaaz, which backed the neurostimulation headphone maker Sychedelic.
Invasive BCI investors back implanted devices like those from Neuralink, Synchron, and Paradromics, which require surgery and long clinical timelines but promise the highest bandwidth. Non-invasive BCI investors back wearable or external systems, such as BrainCo's products, which reach consumers faster but capture weaker brain signals. Many funds, including Khosla Ventures and Dolby Family Ventures, hold positions across both.
tDCS stands for transcranial direct current stimulation, a low-intensity neuromodulation method that passes a weak electrical current through the scalp to influence brain activity. Research summarized by the US National Institutes of Health has studied its effects on focus and mood. Consumer products such as Sychedelic's headphones pair tDCS with audio and biofeedback.
THE INSTRUMENT
Sychedelic combines everything described in this article into one 20-minute protocol.